NRAS Q61	Colorectal Cancer	NRAS Q61	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
NRAS Q61	Colorectal Cancer	NRAS Q61	Colorectal Cancer	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1
NRAS Q61	Melanoma	NRAS Q61	Melanoma	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3
NRAS Q61	Colorectal Cancer	NRAS Q61	Colorectal Cancer	binimetinib Sensitive: C3 – Early Trials binimetinib Sensitive : C3	binimetinib Sensitive: C3 – Early Trials binimetinib Sensitive : C3
NRAS Q61	Melanoma	NRAS Q61	Melanoma	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3
NRAS Q61	Melanoma	NRAS Q61	Melanoma	PD-0325901 + BGB-3245 Sensitive: D – Preclinical PD-0325901 + BGB-3245 Sensitive : D	PD-0325901 + BGB-3245 Sensitive: D – Preclinical PD-0325901 + BGB-3245 Sensitive : D
NRAS Q61	Melanoma	NRAS Q61	Melanoma	PD-0325901 + BGB-283 Sensitive: D – Preclinical PD-0325901 + BGB-283 Sensitive : D	PD-0325901 + BGB-283 Sensitive: D – Preclinical PD-0325901 + BGB-283 Sensitive : D
NRAS Q61	Melanoma	NRAS Q61	Melanoma	sorafenib Sensitive: D – Preclinical sorafenib Sensitive : D	sorafenib Sensitive: D – Preclinical sorafenib Sensitive : D
NRAS Q61	Cholangiocarcinoma	NRAS Q61	Cholangiocarcinoma	NXP800 Sensitive: D – Preclinical NXP800 Sensitive : D	NXP800 Sensitive: D – Preclinical NXP800 Sensitive : D
NRAS Q61	Melanoma	NRAS Q61	Melanoma	cobimetinib + roflumilast Sensitive: D – Preclinical cobimetinib + roflumilast Sensitive : D	cobimetinib + roflumilast Sensitive: D – Preclinical cobimetinib + roflumilast Sensitive : D

NRAS Q61

Associations